Dr Wang has developed a strong background in tissue engineering, biomaterials, cell transplantation, animal models of neurological and cardiovascular diseases, targeted drug delivery and nanotechnology. She obtained a PhD in Biomedical Engineering from Monash University, Australia in 2014, with a thesis on improvement of cell replacement therapy via functionalised composite scaffolds in Parkinson’s diseases. She continued to advance her expertise and pursue studies in stroke repair utilising biological peptide-based scaffolds, which was proven effective in animal models by series of behavioural tests. The first chapter of her research had focused on how bioengineered scaffold evolved from basic polymeric nanomaterials to complex peptide-based scaffolds matrix providing stimulus to manipulate cell engraftment in neurological disease and injuries. In 2016, Dr Wang has broadened her area of research to include drug delivery via targeting peptide technology, developing a glucose-responsive insulin delivery system via modified insulin analogues. She has also extended her research interest into cardiovascular diseases treatment with peptide targeting nanoparticles. Her research output has received research funding from CASS founcation, and recognitions in a number of international awards including International Society for Neurochemistry Award, John Collier Postdoctoral Scholarship, Young Investigator Competition at Asia-Pacific Conference on Medical and Biological Engineering and Florey Postdoctoral Award.